Background Recent evidence suggested that the higher titers of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody from convalescent plasma donors contributed to the clinical improvement in coronavirus disease 2019 (COVID-19) patients. However, the titers of anti -SARS-CoV-2 antibodies varied in each individual, and the precise factors that might govern such variation have not been elucidated. Objectives To assess the factors associated with high titers of anti -SARS-CoV-2 antibody among COVID-19 convalescent plasma (CCP) donors. Methods A cross-sectional study was conducted in Saiful Anwar General Hospital, Malang, Indonesia. Information of interest including demographic characteristics, clinical symptoms, comorbidities, laboratory findings, and the titers of anti -SARS-CoV-2 antibody among COVID-19 CCP donors were collected. The correlation was assessed using multiple logistic regression. Results A total of 50 COVID-19 CCP donors with the titers of anti -SARS-CoV-2 antibody of more than 1:320 and 33 donors with the titers of less than 1:320 were analyzed. Our analysis revealed that CCP donors with history of cough, fever, dyspnea, and pneumonia significantly had higher titers of anti -SARS-CoV-2 antibody compared to asymptomatic donors. Moreover, CCP donors with elevated levels of eosinophils and immature granulocytes and low levels of albumins had higher levels of anti -SARS-CoV-2 antibody. The titer of antibody was not affected by comorbidities of donors. Conclusions CPP donors who had experience of symptomatic COVID-19 with high eosinophils level, high immature granulocytes and low albumin level have higher titers of anti -SARS-COV-2 antibody than those who experienced asymptomatic COVID-19. Our current findings may be used as the additional baseline criteria for selecting the donors of CCP for the management of COVID-19.

Background Heterogeneous respiratory system static compliance (CRS) values and levels of hypoxemia in patients with novel coronavirus disease (COVID-19) requiring mechanical ventilation have been reported in previous small-case series or studies conducted at a national level. Methods We designed a retrospective observational cohort study with rapid data gathering from the international COVID-19 Critical Care Consortium study to comprehensively describe CRS—calculated as: tidal volume/[airway plateau pressure-positive end-expiratory pressure (PEEP)]—and its association with ventilatory management and outcomes of COVID-19 patients on mechanical ventilation (MV), admitted to intensive care units (ICU) worldwide. Results We studied 745 patients from 22 countries, who required admission to the ICU and MV from January 14 to December 31, 2020, and presented at least one value of CRS within the first seven days of MV. Median (IQR) age was 62 (52–71), patients were predominantly males (68%) and from Europe/North and South America (88%). CRS, within 48 h from endotracheal intubation, was available in 649 patients and was neither associated with the duration from onset of symptoms to commencement of MV (p = 0.417) nor with PaO2/FiO2 (p = 0.100). Females presented lower CRS than males (95% CI of CRS difference between females-males: − 11.8 to − 7.4 mL/cmH2O p < 0.001), and although females presented higher body mass index (BMI), association of BMI with CRS was marginal (p = 0.139). Ventilatory management varied across CRS range, resulting in a significant association between CRS and driving pressure (estimated decrease − 0.31 cmH2O/L per mL/cmH20 of CRS, 95% CI − 0.48 to − 0.14, p < 0.001). Overall, 28-day ICU mortality, accounting for the competing risk of being discharged within the period, was 35.6% (SE 1.7). Cox proportional hazard analysis demonstrated that CRS (+ 10 mL/cm H2O) was only associated with being discharge from the ICU within 28 days (HR 1.14, 95% CI 1.02–1.28, p = 0.018). Conclusions This multicentre report provides a comprehensive account of CRS in COVID-19 patients on MV. CRS measured within 48 h from commencement of MV has marginal predictive value for 28-day mortality, but was associated with being discharged from ICU within the same period. Trial documentation: Available at https://www.covid-critical.com/study. Trial registration: ACTRN12620000421932.

Penyakit Paru Obstruktif Kronik (PPOK) dapat ditandai dengan hambatan aliran udara di saluran nafas yang tidak sepenuhnya reversibel. Hasil penelitian pada bulan Januari-Desember 2010 menyebutkan bahwa PPOK menduduki urutan ke-3 dari penyakit paru terbanyak yang ada di RS Paru Batu Malang. Sedangkan di RSU Dr. Saiful Anwar Malang menduduki urutan ke-5. The Burden of Disease Study dibawah naungan WHO menyatakan bahwa pada tahun 2030 PPOK akan menempati peringkat ke-3 penyebab kematian di dunia. Sebagai solusi terhadap masalah tersebut yaitu dengan membangun sebuah aplikasi pengukur kesehatan fungsi paru manusia memanfaatkan microphone pada smartphone". Guna mengetahui gangguan ventilasi paru, monitoring pengobatan, dan menilai perkembangan fungsi paru. Media smartphone dipilih karena memiliki teknologi Microphone API yang digunakan untuk menangkap input berupa rekaman suara hembusan napas pengguna. Dan mayoritas masyarakat telah melilikinya. Dari hasil pengujian validasi dapat disimpulkan bahwa aplikasi pengukur kesehatan paru manusia pada media smartphone berhasil diimplementasikan dengan memanfaatkan teknologi microphone. Dari hasil pengujian akurasi yang dilaksanakan di Rumah Sakit Saiful Anwar Kota Malang dapat disimpulkan bahwa ditemukan selisih akurasi

WHO declared COVID-19 infection as a pandemic since 2020. A rapid noninvasive examination is needed for screening and diagnostic. Exhaled Volatile Organic Compound (VOC) is a sample directly connected to the affected organ, which is the lung, and can be measured as an endogenous volatile marker resulted from oxidative stress. This study aims to analyze differences in VOC concentration in COVID-19 patients with pneumonia and without pneumonia. This Case Control Study used 93 confirmed case samples of COVID-19 and 42 healthy subject. Demographic and clinical data taken from anamnesis and/or medical records. VOC’s data of respiratory track are taken through the exhalation air in a bag and analyzed with breathanalyzer. Statistical analysis was conducted using Mann-Whitney test. In the analysis of confirmed samples of COVID-19 between pneumonia and without pneumonia, co components were found to affect the incidence of pneumonia in confirmed samples of COVID-19 (p=0.003). This conclusion is Components of CO in confirmed COVID-19 have a meaningful effect on an event of pneumonia.

Coronavirus disease 2019 (COVID-19) has emerged as a pandemic across the world. Hypercoagulability status in COVID-19 is one of the causes of complication from severe COVID-19 with a high risk of arterial thrombosis. Acute Limb Ischemia is a vascular emergency caused by sudden decrease in the arterial perfusion. We report the case of a 53-year-old male patient with COVID-19 Pneumonia, diagnosed with Acute Limb Ischemia. From clinical examination, which included anamnesis, physical examination, and laboratory results as well as chest X-rays, a suspicion of Acute Limb Ischemia was found in a patient with COVID-19 pneumonia. The SARS-CoV-2 real time PCR examination showed positive results. In this patient, the diagnosis of Acute Limb Ischemia with Covid-19 Pneumonia was established through a multidisciplinary approach covering the fields of pulmonology, cardiology, and thoracic and cardiovascular surgery. Keywords Acute limb ischemia • ALI • Hypercoagulability • COVID-19 Highlights • The Coronavirus Disease 2019 (COVID-19) is associated with a hyper-coagulability state. • Both arterial and venous thrombosis can occur in COVID-19 associated hypercoagulability state • ALI, a vascular emergency can lead to severe morbidity and mortality.